Focus: MRSA Osteomyelitis
Our lead program, TPH 101, is a monoclonal antibody for the treatment of MRSA osteomyelitis. Osteomyelitis is a devastating bone infection caused by methicillin-resistant Staphylococcus aureus (MRSA) bacteria. This infection can arise from complications of orthopedic surgery (e.g., hip or knee replacement), from orthopedic trauma, or as a complication of diabetes.
The bone loss and tissue damage from these infections can be devastating, resulting in significant morbidity and mortality. With over one million joint replacement procedures performed in the U.S. every year, in addition to the seven million Americans currently living with hip and knee replacements, the need for new treatments to cure MRSA osteomyelitis has never been greater.
At Telephus, we are taking a new approach with TPH 101—a novel monoclonal antibody based on our proprietary immunotherapy platform that enhances the body’s immune system to better fight drug-resistant infections.